{{Use dmy dates|date=August 2016}}

{{Drugbox
| IUPAC_name = (''S'')-3-Phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine
| image = Seproxetine.svg

<!--Clinical data-->
| tradename =  
| pregnancy_category =  
| legal_status = Uncontrolled
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =  
| metabolism =  
| elimination_half-life = 4â€“16 days
| excretion =  

<!--Identifiers-->
| CAS_number = 126924-38-7
| ATC_prefix = none
| ATC_suffix =  
| PubChem = 4541
| IUPHAR_ligand = 208
| DrugBank = DB06731
| ChemSpiderID = 4382
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 25CO3X0R31

<!--Chemical data-->
| C=16 | H=16 | F=3 | N=1 | O=1 
| molecular_weight = 295.30 g/mol
}}

'''Seproxetine''', also known as '''(''S'')-norfluoxetine''', is a [[selective serotonin reuptake inhibitor]] (SSRI).<ref>{{Cite encyclopedia|accessdate=10 August 2016|title=Seproxetine|url=http://www.drugbank.ca/drugs/DB06731|work=DrugBank|publisher=University of Alberta}}</ref> It is the most important [[active metabolite]] of the widely used [[antidepressant]] [[fluoxetine]], but little is known about its pharmacological actions. Seproxetine was being investigated by [[Eli Lilly and Company]] as an antidepressant; however, a cardiac side effect was noted and [[drug development|development]] was discontinued.

== References ==
{{Reflist|2}}

{{Antidepressants}}
{{Anxiolytics}}
{{Monoamine reuptake inhibitors}}
{{Eli Lilly and Company}}

[[Category:Eli Lilly and Company]]
[[Category:Human drug metabolites]]
[[Category:Trifluoromethyl compounds]]
[[Category:Phenol ethers]]
[[Category:Selective serotonin reuptake inhibitors]]

{{nervous-system-drug-stub}}